Purpose: The objective of our study was to determine the maximum tolerable doses (MTDs) of both paclitaxel and cisplatin when given in a weekly schedule alone or simultaneously with G-CSF in advanced solid neoplasms.
Introduction
Paclitaxel (Taxol®; Bristol-Myers Squibb Company, Princeton, NJ) is a new cytotoxic agent extracted from the bark of the Pacific Yew tree, Taxus brevifolia. In spite of the numerous trials conducted, the best dose and schedule of paclitaxel to be employed in combination with cisplatin (CDDP) has not been defined. With the adoption of prophylactic premedication a short-time infusion (even the one-hour administration) has been shown to be as safe as the 24-hour schedule, and is associated with a similar efficacy and lower myelotoxicity. Doses of CDDP and paclitaxel up to 120 mg/m 2 and 225 mg/m 2 , respectively, can be safely administered every three weeks without G-CSF support, when a three-hour schedule is employed [1] .
Weekly fractionation could be a feasible alternative to the standard three-weekly administration, to increase the number of cells exposed to the drug during their progression through the cell cycle. It could be even more appropriate than continuous infusion in most solid tumors, which have a doubling time on the order of several weeks. Weekly administration could also translate into lower toxicity, permitting a higher dose intensity. Akerley et al. [2] administered 175 mg/m 2 /week for at least six weeks in chemotherapy-naive NSCLC patients, with manageable myelotoxicity. Glantz et al. [3] gave a dose even higher (225 mg/m 2 /week) in combination with cranial irradiation in adults with astrocytoma.
In view of these considerations, we planned this phase I study to determine the MTDs of both CDDP and paclitaxel (in a three-hour infusion) when administered together on a weekly schedule. We also chose a weekly schedule for cisplatin, in order to maximize the synergism between these drugs.
Patients and methods

Eligibility
Candidates for this study were patients with histologically-documented solid tumors for which there were no known therapies with greater potential benefit than that of paclitaxel and CDDP. Other eligibility criteria included age <75, ECOG performance status ^2, adequate bone marrow, hepatic, and renal functions, no previous or concurrent malignancy except for inactive non-melanoma skin cancer, and in situ carcinoma of the cervix, or other cancer if the patient had been disease-free for more than five years. All patients gave their written informed consent to participate to this trial, which was approved by the Ethical Committee for Biological Research of the National Tumor Institute of Naples.
Treatment administration
The patients received a combination of CDDP and paclitaxel i.v. weekly, on an outpatient basis, until disease progression, or for a maximum of 12 courses. Paclitaxel was administered over three hours followed by CDDP, which was given over 30 minutes, together with a short-term hyperhydration (two litres of normal saline over four hours) Antiemetic prophylaxis consisted of ondansetron 8 mg i.v. 30 minutes before the start of chemotherapy. All patients received a premedication for hypersensitivity reactions consisting of dexamethasone 20 mg i.v. and promethazine 50 mg i.m. 12 and 1 hour before the start of paclitaxel, and ranitidine 50 mg i.v. 30 minutes before chemotherapy.
Study design
The starting doses of CDDP and paclitaxel were 25 mg/m 2 /week and 45 mg/m 2 /week, respectively. The dosage of the two drugs was alternately escalated by 20% (CDDP = 5 mg/m 2 /week, and paclitaxel 10 mg/nr/week) at each step until dose-limiting toxicity (DLT) occurred in one-third or more of the patients enrolled in that cohort during the first six courses. DLT was defined as: WHO grades 3-4 non-hematologic toxicity (excluding nausea/vomiting or alopecia), or the persistence of grade > 1 neutropenia or thrombocytopenia on the day of recycling. The level at which unacceptable toxicity appeared was evaluated by adding r-HuG-CSF (5 ug/kg s.c. days three to five), if neutropenia had been the only DLT. We decided to stop the dose escalation of CDDP at 40 mg/m 2 , since it was of little interest, in our opinion, to obtain a higher CDDP dose-intensity.
Pretreatment and follow-up studies
The clinical history of all patients was recorded and they underwent physical examination and the usual laboratory studies before chemotherapy. Complete blood cell counts and laboratory tests were repeated weekly, immediately before administration of the chemotherapy. Baseline and post-treatment neurologic examinations included an assessment of muscle strength (by using a dynamometer), sensory perception, and deep tendon reflexes. Toxicities were evaluated according to the WHO toxicity criteria [4] , All of the diagnostic studies required for evaluation of the extent of disease were performed before the start of treatment, and after six and 12 chemotherapy courses.
Results
Fifty-five patients with advanced solid neoplasms (16 lung, 16 breast, 11 ovarian, 7 head and neck, 1 renal, 1 cervical, 1 esophageal, 1 of unknown primary, and 1 softtissue sarcoma) entered this study, for a total of 439 courses delivered. Twenty-five patients were pretreated with chemotherapy. Table 1 summarizes the results of the study. Neutropenia was the principal DLT, occurring in 100/439 courses; it was of grade 4 in only four of the courses. Thrombocytopenia was an uncommon event, occurring in 59 courses (in 11 courses it was of grades 2 ) was considered the maximum tolerable in chemotherapy-naive patients, while the preceding dose level (CDDP 30 mg/m 2 and paclitaxel 55 mg/m 2 ) was safe in pretreated patients.^The addition of G-CSF permitted us to safely escalate the doses of CDDP and paclitaxel in chemotherapy-naive patients to 40 mg/m 2 / week and 85 mg/m 2 /week, respectively. Only one patient showed persistent grade 3 neutropenia at this level.
Neurotoxicity was quite frequent (18 of 55 patients) but never dose-limiting. Altogether, it occurred in 88 courses, but was much more frequent and clinically relevant in patients who had previously received CDDP treatment. Hypersensitivity reactions were uncommon and of little clinical significance.
Overall, 18 patients achieved objective responses (13 of 30 chemo-naTve and 5 of 25 pretreated patients).
Discussion
As yet, the CDDP-paclitaxel weekly administration has not been evaluated in other trials. The doses of paclitaxel we delivered in this study do not seem particularly impressive when compared with the doses of paclitaxel delivered alone in Akerley's and Glantz's studies [2, 3] . The addition of cisplatin and the very restrictive criteria we chose to define the DLT and to stop the recruitment could easily explain our findings. Moreover, the use of high-dose corticosteroids and anticonvulsivants in the Glantz study could provide an additional explanation for the extraordinarily high dose of paclitaxel (225 mg/ m 2 /week) given concurrently with cranial irradiation in that study, since these drugs could have accelerated the paclitaxel clearance.
However, in spite of the very prudent policy we followed, the dose-intensity of CDDP and paclitaxel reached in our study appears quite similar to that obtained with the three-weekly administration [1, 5] .
Moreover, the weekly doses we recommend in the absence or presence of G-CSF support could translate into a higher therapeutical activity than much higher doses given once every three weeks. Longnecker et al. [6] reported a concentration of 0.05 umol/1 at 24 hours after a one-hour infusion of 60 mg/m 2 . Gianni et al. [7] recently reported that a three-hour infusion of 225 mg/m 2 translates into a mean duration of exposure to a concentration above 0.05 umol/1 for only slightly longer (about 27 hours). Since the 0.05 umol/1 concentration was clearly active in vitro [8] , this means that a low weekly dose of paclitaxel may insure a longer overall exposure to active drug levels in a three-week period than the single-day three-weekly administration. The increase in the paclitaxel weekly dose did not result in a clear pharmacokinetic advantage in Glantz's study [3] . In fact, plasma levels > 0.05 umol/1 were maintained for 28 hours with the dose of 100 mg/m 2 and for 21 hours with 225 mg/m 2 .
In conclusion, the CDDP-paclitaxel weekly administration is a safe, practical and effective therapeutical approach for those neoplasms usually considered sensitive to these drugs. Large phase II/III trials are required to evaluate the therapeutical activity of this regimen in sensitive tumors, and to compare the therapeutic index of weekly administration with'that of other schedules.
